Matricelf Ltd. — Investor Presentation 2022

Mar 16, 2022

Autologous 3D Tissue and Organ Production Platform

(TASE:MTLF) Corporate Presentation March 2022

Statement Looking Forward and Disclosure

This presentation was prepared by Matricelf Ltd. ("The Company"), as a general presentation about The Company, as such, the information it includes is only an extract, and does not cover all of the information about The Company and its operations. Therefore, this presentation does not describe The Company's operations fully and detail, and it is not intended to replace the need to review The Company's reports to the public, including the supplementary prospectus of The Company. The information included in this presentation does not purport to survey or include all of the information that could be relevant for the purpose of reaching any conclusion related to investment in the securities of The Company. The Company is also not obligated to update or change the information included in the presentation so that it reflects events or editing, processing or segmentation that differ from the current depiction in the presentation, or change that take the place after the date of its preparation. This presentation includes forward looking information, as defined in the Securities Law 1968 including outlooks, evaluations, estimates and other information related to the events and matters that will take place or may take place in the future, including with regard to the outlook on income and profitability, whose occurrence is not certain and is not under the exclusive control of The Company. Forward looking in the presentation is based on estimates and assumptions of the management of The Company as of the date of that presentation was prepared, which are uncertain by their nature, due to their dependence on the risks inherent in The Company's operations, and which are not under The Company's control, each of which, or a combination thereof, is liable to harm the results of The Company and, consequentially, the realization of this estimates and outlook. The presentation includes statistical data and publications that were published by third parties, the content of which was not examined by The Company, and The Company is not responsible for their validity. The information included in the presentation does not constitute a proposal or invitation to make an offer to purchase The Company's securities.

Company Vision

To become a global leader in the area of Regenerative Medicine and Tissue Engineering, offering innovative implants for a variety of medical conditions affecting millions of patients worldwide

Matricelf Introduction

• Biotechnology company in the field of tissue engineering and regenerative medicine
• Spin-out company from Tel Aviv University, based on years of academic research at Prof Tal Dvir's laboratory, Head of the Nanotechnology center
• Established April 2019
• Completed IPO at TASE in June 2021 (TASE:MTLF)

Matricelf: Overview and Highlights
Innovative approach	• Complete autologous 3D tissue implants for a variety of medical conditions
Unique advantages	• Autologous treatment
	• Complete 3D tissue implant (cells and matrix)
	• Cell differentiation within a 3D structure
	• Thermo-responsive hydrogel enables 3D bioprinting
Main programs	• Spinal Cord Injury (SCI)
	• 3D bioprinting medium production
IP status	• 1 granted patent, 3 pending patents, deep knowhow
Market opportunity	• Addresses unmet need in a multibillion-dollar market
Financial position	• 22 million NIS in cash and cash equivalents as of December 31, 2021
Market capitalization	• 107 million NIS as of March 15, 2022

Proprietary Technologies

Autologous 3D implants:

• Integration of autologous matrix and cells
• Proprietary decellularization of omentum tissue
• Thermo-responsive hydrogel
• In-gel differentiation of induced Pluripotent Stem Cells (iPSC)
• Engineered tissues for several medical indications

3D bioprinting medium:

• Support medium for 3D printing of biomaterials
• Enables 3D printing of volumetric tissues and organs

Spinal Cord Injury (SCI)

SCI Program Highlights

Unmet need • No available treatment for SCI - irreversible loss of motor/sensory/autonomic functions

• Most developed therapies are synthetic/allogeneic which may lead to an immune response
• Our solution 100% autologous tissue engineered product may serve as an ideal solution for SCI patients
  • Personalized treatment, reduced potential immune response
• Market and • ~300,000 SCI patients in the US today

opportunity

timelines

• Approximately 17,000 new SCI cases per year in the US
• Huge economic impact on society and healthcare systems
• Regulation Classification: Advanced Therapy Medicinal Product (ATMP)
  • PreIND meeting with FDA March 2021
• Status and • Current status – R&D, preclinical studies
  • First in Human (FIH) clinical trial end 2024-beginning 2025, Israel

Matricelf Platform Genetares Autologous Functioning 3D Neural Implants for SCI

Functional Neural Implant

• ü Incorporation of iPSCs within extracellular matrix followed by controlled differentiation
• ü New synapses and neurons creating a neural network
• ü Matured 3D tissue

Cell Function within Neural Implants

Neurite outgrowth of neural implant Neurite network between neural

2 mm

implants

Mice Treated with Neural Implants Regained Their Walking Abilities

Control

• Two months follow up post spinal hemi-section in mice
• "Cat walk" four limbs motor function and gait analysis
• Control group hemiparesis (circled in red)
• Mice treated with neural implants regained their walking abilities

Usability Studies with Neural Implants in Porcine

Neural implants placed in a porcine spinal cord cavity

Competitive landscape

Matricelf develops a one-of-a-kind technology that produces functioning, completely autologous, 3D neural implants

2021 Key Achievements

• Completed tech-transfer from Tel Aviv University
• FDA Pre-IND meeting
• TASE IPO (MTLF) ~ USD 7.5M
• New lab opening
• National Ethics committee approval (Animal trials)
• Completed development of human hydrogel
• Successfully completed usability studies
• Institutional Review Board (IRB) approval at Herzliya Medical Center (Omentum biopsies)
• New license agreement with Tel Aviv University ("Ramot")-Support medium for 3D printing of biomaterials

During the upcoming year the company plans to complete the development work of neural human implants including QC methods and full QC release of the implants and implants raw materials: hydrogel and induced Pluripotent Stem Cells (iPSCs).

Management Team

TAL DVIR, PhD Founder, CSO

ASAF TOKER, MD CEO

TAMAR HAREL ADAR, PhD VP R&D

TAL BEN NERIAH, MSc. Director of Operations

SIGAL RUSSO, CPA

Board of Directors

TAL DVIR, PhD member

RUTH ARNON, PhD member

DORON BIRGER Chairman

RIVKA CARMI, MD member

Ori Hershkovitz

member

ALON SINAI member

Neomi Enoch, CPA member

Scientific Advisory Board

NICHOLAS THEODORE, MD

Professor of Neurosurgery and the director of the Johns Hopkins Neurosurgical Spine Center.

ECKHARD VON KEUTZ, PhD

Chairman of the Advisory Board of the Fraunhofer Institute of Toxicology and Experimental Medicine

MARK TUSZYNSKI, MD PhD

Director of The Center for Neural Repair, University of California, San Diego

Executive Director of the Harvard Stem Cell Institute.

KAPIL BHARTI, PhD BROCK REEVE, PhD

Senior researcher at the National Institutes of Health ("NIH")

Financial Figures

• TASE IPO (MTLF) ~ USD 7.5M 24 million NIS
• 22 million NIS in cash and cash equivalents as of December 31, 2021
• Market cap of 107 million NIS as of March 15, 2022

	Investment Summary
	Significant market potential	•	~300,000 SCI patients in the US today
		•	Approximately 17,000 new SCI cases per year in the US
		•	Huge economic impact on society and healthcare systems
		•	Addresses unmet need in a multibillion-dollar market
		•	Estimated cost for care for first year post -SCI \$350K-\$1M
		•	Lifetime medical costs for a quadriplegic patient injured at the age of 25 is estimated at \$4.8M
	Value proposition	•	100% autologous neural tissue
		•	Personalized treatment, reduced potential immune response
	Regulatory pathway	•	Classification: Advanced Therapy Medicinal Product (ATMP)
		•	PreIND meeting with FDA – March 2021
	Strong IP	•	1 granted patent, 3 pending patents, deep knowhow
	Experienced team	•	10 employees
		•	highly experienced board and scientific advisory board